中国人群使用曲美他嗪治疗稳定型心绞痛疗效评价  

A Systematic Review of Efficacy of Trimetazidine for Stable Angina Pectoris in Chinese People

作　　者：章锦丽 杨雪[2] 张惠霞[2] 卢洁[3] 王丽[2] 程刚[4] 

机构地区：[1]河南省食品药品监督管理局,河南郑州450000 [2]河南省食品药品评价中心,河南郑州450004 [3]郑州大学公共卫生学院,河南郑州450001 [4]国家食品药品监督管理局药品评价中心,北京100045

出　　处：《中国药物警戒》2013年第12期723-729,共7页Chinese Journal of Pharmacovigilance

摘　　要：目的系统评价曲美他嗪治疗稳定型心绞痛(stable angina pectoris,SAP)的临床疗效。方法 2012年10月以曲美他嗪相关药品名称、口服制剂等做检索词,检索PubMed、Embase、Cochrane、中国生物医学文献数据库(CBM)、中国期刊全文专题数据库(CNKI)、中国科技期刊数据库(VIP)及万方数据库等,按纳入与排除标准选择文献并进行资料提取和质量评价后,采用Meta分析等统计学方法对曲美他嗪治疗稳定型心绞痛的疗效作系统评价。结果共纳入13个RCT,869例患者。Meta分析结果显示:在总有效率、每周心绞痛发作次数、每周硝酸甘油消耗量、ST段压低1mm阈值、心绞痛发作阈值5个方面,治疗组均明显优于对照组;而在运动持续时间方面,不支持曲美他嗪有增加患者运动持续时间的作用。结论曲美他嗪治疗稳定性心绞痛的疗效优于常规对照组,但因纳入的研究存在一定的方法学缺陷,本研究结论尚需进一步开展严格设计的大样本、多中心、随机双盲对照试验来证实。Objective To evaluate the effcacy of trimetazidine（TMZ） in the treatment of stable angina pectoris（SAP）. Methods All hteratures related to trimetazidine were retrieved in the following databases as PubMed, EMbase, Cochrane Central Database, CBM, CNKI, VIP and WanFang Data. The literatures which met the inclusion and exclusion criteria were selected, data were extracted, the quality was evaluated, and then statistical methods such as Meta-analysis were performed. Results A total of 13 RCTs involving 869 patients were included. The Meta-analysis showed that, compared with the control group, TMZ was significantly superior in the following 5 aspects： total eflfciency, weekly mean number of angina attacks, weekly nitroglycerin consumption, the time to 1 mm drop of ST segment and angina pectoris threshold. But TMZ has no significant difference in duration of doing exercise compared with the control group. Conclusion Based on current studies, for SAP at present. However, due to defect of the data TMZ is superior to other medicines in the control group analysis method, this conclusion needs to be confirmed by more high quality, large sample, multi-center, double blind RCTs

关 键 词：中国人群 曲美他嗪 稳定型心绞痛 疗效 META分析 

分 类 号：R453[医药卫生—治疗学]